News
OCUL
--
0.00%
--
Do Institutions Own Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares?
The big shareholder groups in Ocular Therapeutix, Inc. (NASDAQ:OCUL) have power over the company. Generally speaking...
Simply Wall St. · 3d ago
Ocular Therapeutix (OCUL) Presents at H.C. Wainwright Annual Global Investment Conference - Slideshow
The following slide deck was published by Ocular Therapeutix, Inc. in conjunction with this event.
Seekingalpha · 09/18 17:37
Ocular Therapeutix Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Post-Surgical Ocular Inflammation and Pain in Children
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patients in a Phase 3 clinical trial of DEXTENZA® (dexamethasone
Business Wire · 09/10 12:00
Dosing underway in Ocular Therapeutix's Dextenza study for post-surgical inflammation in children
Ocular Therapeutix (OCUL) has dosed the first patients in a Phase 3 clinical trial of DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for the treatment of post-surgical ocular inflammation and pain
Seekingalpha · 09/10 11:36
Ocular announces resolution of FDA warning letter for its ophthalmic sealant
Ocular Therapeutix (OCUL) up ~3% in premarket after it received a letter from the FDA closing out the warning letter it received from the FDA in October 2018, related to its ReSure Sealant.The
Seekingalpha · 09/08 12:22
Ocular Therapeutix Announces Successful Resolution of FDA Warning Letter Related to ReSure® Sealant
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced it has received a letter from the U.S. Food and Drug Administration (FDA) dated September 2, 2020
Business Wire · 09/08 12:00
Ocular Therapeutix Announces Successful Resolution Of FDA Warning Letter Related To ReSure Sealant
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced it has received
Benzinga · 09/08 11:01
Billionaire Ken Griffin Snaps Up These 3 “Strong Buy” Stocks
TipRanks · 09/04 16:52
Ocular Therapeutix to Present at Two Upcoming Investor Conferences
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present and host investor meetings at the following conferences:
Business Wire · 09/03 12:00
Ocular - Small-Cap Pharmaceutical Growth Story
The newest program, OTX-DED, is possibly the next one to enter the market.Rebate of work done with 0356T might drive adoption by new clinics.Dextenza sales poised for fast growth in 2020 and into 2021.
Seekingalpha · 09/02 17:05
The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/27 12:02
Ocular Therapeutix EPS misses by $0.32, misses on revenue
Ocular Therapeutix (NASDAQ:OCUL): Q2 GAAP EPS of -$0.64 misses by $0.32. Revenue of $1.57M (+141.5% Y/Y) misses by $0.03M. Press Release
seekingalpha · 08/07 16:17
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -6.25% and -1.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/07 12:45
Ocular Therapeutix: Q2 Earnings Insights
Shares of Ocular Therapeutix (NASDAQ:OCUL) moved higher by 1% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were down 12.28% year over year to ($0.64), which missed the estimate of ($0.31).Revenue of $1,569,00
Benzinga · 08/07 11:34
Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the second quarter ended
Business Wire · 08/07 11:15
Earnings Outlook for Ocular Therapeutix
Ocular Therapeutix (NASDAQ: OCUL) announces its next round of earnings this Friday, August 07. Here is Benzinga's look at Ocular Therapeutix's Q2 earnings report.Earnings and Revenue Sell-side analysts are expecting Ocular Therapeutix's loss per share to be ne
Benzinga · 08/06 20:08
Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings?
Ocular Therapeutix (OCUL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 08/06 12:37
Ocular Therapeutix™ To Report Second Quarter 2020 Financial Results
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter ended June 3
Business Wire · 07/31 11:00
Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Should You Buy?
Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/29 16:33
MAC establishes physician fee schedule for intracanalicular inserts
Ocular Therapeutix (OCUL +2.4%) announces that First Coast Service Options is the second Medicare Administrative Contractor (MAC) to establish a physician
seekingalpha · 07/23 21:13
Webull provides a variety of real-time OCUL stock news. You can receive the latest news about Ocular through multiple platforms. This information may help you make smarter investment decisions.
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
More